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Prostate cancer (PCa) is the second leading cause of cancer-related
death in men in the United States (Greenlee et al, 2001) and also is
a common cancer increasing in Japan (Yamamoto, 1999). Current
staging modalities in predicting locally advanced and metastatic
PCa include serum prostate-specific antigen (sPSA) level, trans-
rectal ultrasound (TRUS), computed tomography (CT) scan
(Catalona et al, 1994). PSA, which belongs to the tissue kallikrein
family, is primary produced by the prostatic epithelium and the
secretion is regulated by the androgen level (Webber et al, 1996).
PSA secretion is tissue specific, and elevated sPSA is an effective
marker for identifying men who have PCa (Crawford et al, 1997).
However, it is also often elevated in men with benign prostatic
hyperplasia (BPH), prostatitis and other non-malignant disorders
(Crawford and DeAntoni, 1993). Therefore, to obtain clinical
diagnosis, prostate biopsy is performed. However, in other urolog-
ical tumours like renal cell cancer (RCC), biopsy is not a common
modality for diagnosis, since it might cause cancer cells dissemi-
nation into blood flow or surrounding tissues and contribute to
disease progression (Smith, 1984; Kiser et al, 1986). This point is
not negligible also when regarding prostate cancer, and the impli-
cation in biopsy and possible tumour dissemination needs to be
investigated. Despite the clinicopathological stage of the disease in
the patients with PCa, the frequency of detection of distant metas-
tasis by routine clinical analysis is not concordant with the
frequency of disease recurrence after definitive local therapy
(Levine et al, 1986). 
Reverse transcription polymerase chain reaction (RT-PCR) is a
sensitive and useful method for detecting the presence of a specific
cell type such as those bearing tumour-specific mRNA. Recently,
several studies reported the presence of PSA-mRNA bearing cells,
most likely PCa cells, in the peripheral blood using RT-PCR. Their
detection rates in PCa patients were reported as 0 ˜
88% (Gomella
et al, 1997; Corey and Corey 1998; Fadlon and Hamdy, 1998;
Berteau et al, 1999; de la Taille et al, 1999). Although it has been
reported that prostate massage, digital rectal examination and ejac-
ulation raise sPSA levels to some extent (Yuan et al, 1992; Zisman
et al, 1997), the presence of PSA-mRNA-bearing cells in the
peripheral blood following these events has been seldom reported.
Furthermore, the higher frequency of PSA-mRNA-bearing cells in
the peripheral blood was correlated with the extent of the disease
(de la Taille et al, 1999; Mejean et al, 2000; Su et al, 2000). Thus,
the presence of PSA-mRNA-bearing cells in peripheral blood after
biopsy might contribute to tumour progression leading to poorer
prognosis. In the present study, we further examined the relation-
ship between clinicopathological findings and those detected using
nested RT-PCR in prostate cancer patient’s peripheral blood. 
MATERIALS AND METHODS 
Patients and their clinicopathological characteristics 
A total of 108 patients with serum PSA levels elevated more than
4.0 ng ml–1 were selected for this study. Patient characteristics are
presented in Table 1. Informed consent to perform the study was
obtained from all patients. Systemic sextant prostate biopsy was
performed using transrectal ultrasound between October, 1998 and
April, 2000, and if a hypoechoic lesion or hypervascular lesion
was seen, an additional directed biopsy was performed when
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survival were investigated in March 2001, and the mean observa-
tion periods were 17.8 and 17.1 months, respectively. 
Blood samples and total RNA extraction 
Peripheral blood samples were obtained before and within 10
minutes after prostate biopsy. Total RNA was extracted from 1 ml
of whole blood anticoagulated with EDTA using an SV total RNA
isolation system (Promega, Madison, Wisconsin). 
RT-PCR 
Nested PCR using outer and inner primer sets were applied. The
sequences used for external PSA 20-mer primers were obtained
from GenBank and were selected for lowest homology with human
kallikrein nucleotide sequences examined by BLAST search. Outer
primers were previously reported to identify circulating prostate
tumor cells in blood (Ferrari et al, 1997). They were anchored in
exon 3 at nucleotides 648–667 (5′ -GATGACTCCAGCCAC-
GACCT-3′ ) and in exon 5 at nucleotides 1357–1338 (5′ -CACAGA-
CACCCCATCCTATC-3′ ). The nested PSA 20-mer primers were
designed to be anchored in exon 4 at nucleotides 860–879 (5′ -
GCAAGTTCACCCTGAGAAGG-3′ ) and in exon 5 at nucleotides
1315–1296 (5′ -GATATGTCTCCAGGCATGGC-3′ ). 
The first strand DNA was synthesized using a single strand
cDNA synthesis kit (Boehringer Mannheim, Inc, Mannheim,
Germany) according to the manufacturer’s instructions. Resulting
cDNA was amplified by nested PCR in a thermal cycler 9600
(Perkin-Elmer, Norwalk, Connecticut). We amended the RT-PCR
methods reported previously (Saito et al, 1996; Ferrari et al, 1997). 
To control for RNA integrity and to determine the significance
of a negative PCR assay, we performed an RT-PCR assay
involving the product of the housekeeping gene beta-actin. A set of
20-mer primers anchored at nucleotides 416–435 (5′ -GATAT-
GTCTCCAGGCATGGC-3′ ) and nucleotides 859–840 (5′ -
GATATGTCTCCAGGCATGGC-3′ ) of the beta-actin cDNA was
synthesized to amplify a fragment of 520 bp. 
3 negative control reactions were included in the PSA PCR
experiment  – a reaction with no added cDNA and a reaction
containing human female peripheral blood mononuclear cells
cDNA and that of healthy young males. A reaction containing
cDNA synthesized from RNA derived from a mixture of one
LNCaP cell and 1 ml of whole peripheral blood served as a positive
control in each experiment. Dilutions of LNCaP were prepared as
follows. LNCaP cells were counted in a chamber, and 1000 and 100
cells were directly diluted in 1 ml of whole blood anticoagulated
with EDTA. 100 cells were further subjected to serial dilutions to
furnish 10 cells and 1 cell in 1 ml. To confirm the reproducibility of
the procedure, it was repeated 5 times which demonstrated same
results, one of which is represented in Figure 1. 
Sequencing 
The PCR products were electrophoresed in agarose gel elec-
trophoresis and stained with ethidium bromide to confirm the
products were derived from PSA-mRNA, the nucleotide sequences
of some PCR products were sequenced. Briefly, purified products
from agarose gel using Suprec 01 DNA recovery tubes (Takara,
Japan), were directly determined on an ABI Prism 310 Genetic
Analyzer (Perkin Elmer Japan Applied Biosystems). Labeling was
performed with an inner PCR primer and a BigDye Terminator RR
Mix (Perkin Elmer Japan Applied Biosystems). Each sequence
was verified in both the sense and antisense directions (data not
shown). 
Statistical analysis 
Statistical comparisons were made using the Welch corrected t-test
and χ 2 tests in StatView 5.0 software for a Macintosh computer.
Survival curves were generated using the method of Kaplan and
Meier, and differences between curves were evaluated using the
log-rank test. 
RESULTS 
PSA RT-PCR analysis of peripheral blood samples 
RNA was extracted from the peripheral blood of 119 patients
before and after prostate biopsy. As a first step, beta-actin PCR
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Table 1 Patient characteristics 
Number of  Age (mean)  sPSA (mean)  P. volume  PSAD (mean)  
patients y. o. ng ml–1 (mean) cm3 ng ml–1 cm–3
BPH 62 52–90 (70) 4.0–32.5 (8.9)* 14.2–120 (38.6) 0.08–1.22 (0.23)* 
PCa 46 42–90 (72) 4.0–1121 (72.1) 15.3–72.0 (42.2) 0.08–15.8 (1.71) 
Total 108 42–90 (70) 4.0–121 (35.8) 14.1–120 (39.6) 0.08–15.8 (0.86) 
*P < 0.05. 
Figure 1 Detection of PSA-mRNA by single (upper panel – 710 bp) and
nested (middle panel – 455 bp) RT-PCR. Beta-actin as a control mRNA
(lower panel – 520 bp). Lane 1, molecular weight marker. Zero (lane 2), One
(lane 3), 10 (lane 4), 100 (lane 5) and 1000 (lane 6) LNCaP human PCa cells
were mixed with 1 ml of human female peripheral blood and amplified by RT-
PCR. Zero (lane 2) was one of the negative controls and NC (lane 7) was
also a negative control with a reaction containing peripheral blood
mononuclear cells cDNA of a healthy young male. Another negative control
without cDNA was prepared (data not shown). PC (lane 8) was a positive
control 
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3 NC. PC.assay was performed to evaluate RNA integrity. 11 cases were
excluded because of degradation of RNA. RNA samples from 108
patients were examined using RT-PCR. PSA-mRNA was detected
in 3 PCa but in no BPH cases before biopsy. In 37 cases (16 of 62
BPH cases (25.8%) and 21 of 46 PCa cases (45.7%), PSA-mRNA
was detected only after biopsy. There was no case, in which PSA-
mRNA bearing cells were detected in peripheral blood before
biopsy became undetectable after the biopsy. In Figure 2, represen-
tative RT-PCR findings from 4 PCa patients and 2 BPH patients are
shown. PSA PCR product bands both before and after the biopsy
were observed in Pt. No. 1, and 26. Pathological diagnosis of these
were PCa, both of which had distant metastases and elevated sPSA
of 380 ng ml–1 and 376.8 ng ml–1, respectively (Figure 2). 
Comparison of clinicopathological parameters and PSA
RT-PCR assay findings 
The 3 cases with detectable PSA-mRNA before biopsy were all
PCa with extraprostatic disease (T3 or T4 and/or N1 and/or M1)
and had higher sPSA levels and PSA density (PSAD) than the other
105 cases with negative RT-PCR assay (P < 0.001) (Figure 3A, B).
The patients with positive PSA-mRNA after biopsy either likely
had higher sPSA levels than those with negative mRNA (77.4 ng
ml–1 versus 11.3 ng ml–1, P < 0.05), or PSAD levels (1.72 ng ml–1
cm–3 versus 0.35 ng ml–1 cm–3, P < 0.05) (Figure 3C, D). A signifi-
cant difference between the proportion of positive PSA-mRNA
among PCa cases (52.2%) and BPH cases (25.8%) was observed
after biopsy, and this significance could also be observed between
these 2 groups with gray zone sPSA (4.0–10.0 ng ml–1) (Figure 4). 
The clinical stages and PSA RT-PCR findings of 46 PCa patients
are presented in Table 2. A significant difference between the
proportion of positive PSA-mRNA among the PCa cases with
extraprostatic disease (3 of 11 cases – 27.3%) and organ confined
disease (T1 or T2, N0, M0) (0%) was observed before biopsy (P <
0.01) (Table 2), but other clinical tumour stages were not correlated
with RT-PCR findings. Among 46 PCa patients, no correlation was
observed between positivity of RT-PCR and pathological differenti-
ation, grade or Gleason score, but positive PSA-mRNA cases had
more cancer involved biopsy cores (mean 4.2) than negative PSA-
mRNA cases (mean 2.2) after biopsy, and the difference was signif-
icant (P < 0.001) (Figure 5). 
All 46 PCa patients were treated with combined androgen
blockade following diagnostic procedures involving prostate
biopsy, and 6 and 2 cases of these underwent radical prostatectomy
and radiation therapy, respectively. 1 case with positive PSA-
mRNA after biopsy and 1 with negative mRNA, died of disease-
specific causes. Disease progressions showing new metastatic sites
were identified in 5 cases with positive PSA-mRNA and one with
negative mRNA with imaging such as CT or isotope bone scans.
The disease progression-free survival rate was lower in the N0, M0
cases with positive PSA-mRNA after biopsy than in the N0,
M0 cases with negative mRNA, however, the difference was not
significant (Figure 6). 
DISCUSSION 
Recent studies showed tumour cells circulating in peripheral blood
were observed in several cancers including RCC or breast cancer,
and the consequence in disease staging or prognosis has been
demonstrated (de la Taille et al 2000; Sabbatini et al 2000). In the
present study, PSA-mRNA-bearing cells circulating in peripheral
blood before prostate biopsy were identified in 3 of 11 cases
(27.3%) of PCa with extraprostatic disease. These findings suggest
that detection of circulating prostate cells would enable molecular
staging in patients with PCa. However, 8 cases with extraprostatic
disease including 1 patient with clinical stage T4, N0, M0 and
1121 ng ml–1 of sPSA showed negative RT-PCR before biopsy.
New strategies for accurate staging of the disease have been tried
including flowcytometric detection of PSA-positive cells in
peripheral blood (Eskola et al, 1994). RT-PCR is the most sensitive
method and applicable to the molecular staging (Corey et al, 1998;
Okegawa et al, 2000). Moreno et al, first applied PCR technology
to the identification of circulating PSA-mRNA signals in patients
with metastatic PCa and demonstrated a sensitivity of 33% (Moreno
et al, 1992). Although detection rates of PSA-mRNA positive cells
in peripheral blood of prostate cancer patients varied between 0 and
88%, with more accurate molecular biological techniques staging
before surgery may be achieved. However, no standard RT-PCR
procedure has been established for detecting PSA-mRNA-bearing
cells in peripheral blood. The difference depends upon sample
collection and fractionation, storage, reverse transcription and
amplification. 
The present RT-PCR detected the presence of PSA-mRNA in
peripheral blood in 40 of 108 (37.0%) patients after sextant
prostate biopsy using TRUS. Among them, 37 patients (34.3%)
were negative for PSA RT-PCR before biopsy. Moreno et al,
reported among 43 TRUS cases, 42 cases were negative before
biopsy and 4 cases (9.5%) converted to a positive RT-PCR PSA
findings (Moreno et al, 1997). Although the present methods for
sample collection and RNA extraction differed from those of
Moreno et al, the possibility of tumour spreading by prostate
biopsy appears to be greater than that of previous studies. 
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Figure 2 Representative findings of nested RT-PCR. Pt. No. 1 and
Pt. No. 26 are PCa cases with distant metastasis. Pt. No. 53 and Pt. No. 62
are PCa cases without distant metastasis. Pt. No. 54 and Pt. No. 99 are BPH
cases. PC and NC are positive and negative controls 
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Table 2 Summary of clinical stages of PCa cases and PSA RT-PCR
findings 
PSA-mRNA (+)  PSA-mRNA (+) 
before biopsy after biopsy 
Organ confined disease (n = 35) 0/35* 16/35 
T1 (n = 22) 0/22* 4/22 
T2 (n = 13) 0/13* 12/13 
Extraprostatic disease (n = 11) 3/11* 8/11 
T3 (n = 2) 1/2 2/2 
T4 (n = 1) 0/1 1/1 
N1 and/or M1 (n = 8) 2/8 5/8 
Total (n = 46) 3/46 24/46 
*P < 0.01. The present study showed that the detection rate of PSA-mRNA
after biopsy was higher in those with elevated sPSA (P < 0.05) or
PSAD (P < 0.05) indicating a higher likelihood of the presence
of PCa. Indeed, the detection rate was higher in the PCa group 
(P < 0.01) and, the patients with more positive cores had more
frequency of PSA-mRNA-bearing cells in peripheral blood 
(P < 0.001). This finding suggests that PSA-mRNA after biopsy
might have a diagnostic value, and especially with higher volume
cancer cases, prostate biopsy might scatter the prostate
constructing cells or prostate cancer cells into the blood stream,
which might contribute to micrometastasis. However, PSA-mRNA
were detected in also non-PCa cases indicating the presence of
PSA-mRNA does not necessarily mean the presence of prostate
cancer cells in peripheral blood. 
Implantation of tumour cells along the needle tract or dissemi-
nation in patients with cancer is a rare but potential complication
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Figure 4 Proportion of positive PSA RT-PCR cases before and after biopsy,
and proportion of positive PSA RT-PCR cases after prostate biopsy in
patients with grey zone sPSA (4.0–10.0 ng ml–1) 
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Figure 3 (A) sPSA level in the PSA RT-PCR-positive and -negative groups before biopsy. (B) PSAD in the RT-PCR-positive and -negative groups before
biopsy. (C) sPSA level in the RT-PCR-positive and -negative groups after biopsy. (D) PSAD in the RT-PCR-positive and -negative groups after biopsy 
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Figure 5 Correlation of number of cancer positive cores and PSA RT-PCR
findings after biopsy in PCa patients following percutaneous needle biopsy, and was reported as chest
wall implantation of lung cancer and breast cancer after fine needle
aspiration biopsy (Voravud et al, 1992; Paik et al, 1994), and also
as tumour extension along a biopsy needle tract from RCC (Smith
et al, 1984; Kiser et al, 1986). However, it is still controversial
whether surgical manipulation or biopsy of the prostate causes
dissemination and/or micrometastasis of prostate cancer cells. RT-
PCR is an extremely sensitive method to detect specific mRNA-
bearing cells in the blood stream. It can detect a single specific
mRNA-bearing cell among 10–108 cells (Raj et al, 1998). Some
studies reported that at least 104 circulating tumour cells are
required for metastasis (Liotta et al, 1976). Moreover, only 0.01%
of circulating cancer cells create a single metastasis (Fidler, 1990;
Fadlon et al, 1996). Thus, a correlation between prognosis and
detection of cancer cells in blood after surgery or biopsy are
needed to clarify their clinical significance. Although the clinico-
pathological background and tumour biological behaviour in
patients in the current study varied, the PSA-mRNA positive group
after biopsy demonstrated a tendency towards decreased disease
progression-free survival, indicating PSA-mRNA in blood after
biopsy might have a prognostic value of disease progression-free
survival. A long observation period is required to draw a definite
conclusion and another modality to improve the information such
as quantitative RT-PCR appears to be necessary for estimating the
correlation between the number of circulating prostate cells and
the presence of metastases or further disease progression after the
biopsy. 
It is concluded that nested RT-PCR could detect tumour cells in
peripheral blood with higher sensitivity prior to metastases, enabling
molecular staging of the tumour. We have also demonstrated that
TRUS prostate biopsy might disperse prostate cells into the blood
stream especially in cases with high sPSA. The prognosis for
patients with clinically localized PCa and a positive PSA RT-PCR is
currently not known. Although a prospective study comparing with
the clinical course is required, to avoid dissemination of the tumour
cells a minimal number of core biopsies for clinically and firmly
diagnosed PCa should be adequate. To estimate the significance of
detection of PSA-mRNA-bearing cells in the peripheral blood for
metastasis and survival, further studies are warranted. 
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Figure 6 Disease progression-free survival of N0, M0 cases categorized
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